Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

NCT05425940 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT05425940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05425940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Lead sponsor
Exelixis
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 7, 2022
Completion date
January 31, 2027
Enrollment
901 (actual)
Sites
133

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer